Understanding how cholangiocarcinoma develops at the molecular level
Deciphering the Molecular Mechanisms Underlying Cholangiocarcinoma Development
This study is looking into how cholangiocarcinoma, a cancer that affects the bile ducts, develops, especially in people with certain liver conditions, to find ways to detect it early and improve treatment options.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Pittsburgh at Pittsburgh NIH-funded |
| Lab location | 1 site (Pittsburgh, United States) |
| Project ID | NIH-11106737 on NIH RePORTER |
What this research studies
This research investigates the complex biological mechanisms that lead to the development of cholangiocarcinoma (CCA), a type of cancer affecting the bile ducts. It aims to identify biomarkers that could enable early detection and prevention of CCA, particularly in patients with cholestatic diseases like primary sclerosing cholangitis. The study will explore the roles of specific receptors in tumor formation and the tumor microenvironment, using advanced molecular techniques to analyze cellular changes. By understanding these processes, the research seeks to improve treatment options and outcomes for patients at risk of CCA.
Who could benefit from this research
Good fit: Ideal candidates for this research include individuals diagnosed with cholestatic diseases, particularly those with primary sclerosing cholangitis, who are at increased risk for developing cholangiocarcinoma.
Not a fit: Patients without cholestatic diseases or those who do not have a family history of biliary cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to earlier detection and better prevention strategies for cholangiocarcinoma, significantly improving patient survival rates.
How similar studies have performed: Previous research has shown promise in identifying biomarkers for other types of cancers, suggesting that this approach may yield valuable insights for cholangiocarcinoma as well.
Where this research is happening
Pittsburgh, United States
- University of Pittsburgh at Pittsburgh — Pittsburgh, United States (Active)
Researchers
- Principal investigator: Ko, Sungjin — University of Pittsburgh at Pittsburgh
- Study coordinator: Ko, Sungjin
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.